Now showing items 1-1 of 1

    • Combined inhibition of MEK and Plk1 has synergistic anti-tumor activity in NRAS mutant melanoma 

      Posch, C; Cholewa, BD; Vujic, I; Sanlorenzo, M; Ma, J; Kim, ST; Kleffel, S; Schatton, T; Rappersberger, K; Gutteridge, R; Ahmad, N; Ortiz/Urda, S (2015)
      About one third of cancers harbor activating mutations in rat sarcoma viral oncogene homolog (RAS) oncogenes. In melanoma, aberrant neuroblastoma-RAS (NRAS) signaling fuels tumor progression in about 20% of patients. Current ...